 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GlycoMimetics doses first cohort in GMI-1687 study

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced dosing...

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on...

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

GlycoMimetics, Inc. (the Company) (NASDAQ:GLYC) today announced that the Compensation Committee of the Companys Board of Directors approved the grant on August 14 , 2023 of a non-qualified stock...

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem...

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem

GlycoMimetics, Inc. (NASDAQ:GLYC  Free Report)  Investment analysts at HC Wainwright increased their Q3 2023 earnings estimates for GlycoMimetics in a report issued on Thursday, August 3rd. HC Wainwright analyst E. White now expects that the biotechnology company will earn ($0.14) per ...

Q3 2023 EPS Estimates for GlycoMimetics, Inc. Increased by HC Wainwright (NASDAQ:GLYC)

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023. Cash and cash equivalents as...

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript

GlycoMimetics Q2 2023 Earnings Preview

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial...

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Watchers	5,376
52-Wk Low	$0.55
52-Wk High	$4.16

Market Cap	$90.69M
Volume (M)	230,114.00
52-Wk High	$4.16
52-Wk Low	$0.55

GLYC GlycoMimetics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals